Regeneron Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Regeneron Pharmaceuticals Inc. (REGN)

Q2 2012 Earnings Call

July 25, 2012 8:30 am ET

Executives

Dr. Leonard Schleifer – President, Chief Executive Officer

Murray Goldberg – Chief Financial Officer

George Yancopoulos – Chief Science Officer, President – Regeneron Research Labs

Robert Terifay – Senior Vice President, Commercial

Dr. Michael Aberman – Vice President, Strategy and Investor Relations

Analysts

Steve Byrne – Bank of America

Alethia Young – Deutsche Bank

Chris Raymond – Robert W. Baird

Terence Flynn – Goldman Sachs

Jim Birchenough – BMO Capital

Yaron Werber - Citigroup

Biren Amin – Jefferies

Mani Mohindru – ThinkEquity

Joseph Schwartz – Leerink Swann

Ted Tenthoff – Piper Jaffray

Phil Nadeau – Cowen & Company

Geoff Meacham – JP Morgan

Presentation

Operator

Good morning ladies and gentlemen and welcome to the Regeneron Pharmaceuticals conference call to discuss the second quarter 2012 financial results. My name is Kevin and I’ll be your coordinator today. At this time, all participants are in a listen-only mode. We will conduct a question and answer session towards the end of this conference call. As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the call over to Dr. Michael Aberman, Vice President of Strategy and Investor Relations for Regeneron. Please proceed, Dr. Aberman.

Dr. Michael Aberman

Thank you, Operator, and good morning and welcome to Regeneron Pharmaceuticals’ second quarter 2012 conference call. An archive of this webcast will be available under Events and Presentations for 30 days. Joining me on the call today is Dr. Leonard Schleifer, the Founder, President and Chief Executive Officer; George Yancopoulos, Executive Vice President, Chief Scientific Officer and President of Regeneron Research Labs; Murray Goldberg, Chief Financial Officer, and Robert Terifay, Senior Vice President, Commercial. After our prepared remarks, we’ll open the call for Q&A.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round